multicenter, randomized, double-blind low-dose vasopressinnorepinephrine 396 patients 382 patients...
TRANSCRIPT
![Page 1: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/1.jpg)
![Page 2: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/2.jpg)
![Page 3: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/3.jpg)
![Page 4: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/4.jpg)
![Page 5: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/5.jpg)
![Page 6: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/6.jpg)
![Page 7: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/7.jpg)
![Page 8: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/8.jpg)
![Page 9: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/9.jpg)
July 3, 2008
![Page 10: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/10.jpg)
![Page 11: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/11.jpg)
December 18, 2008
![Page 12: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/12.jpg)
(relative risk of survival, 0.87; 95% confidence interval, 0.65 to 1.15; P =
0.36)
![Page 13: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/13.jpg)
June 5, 2008
![Page 14: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/14.jpg)
![Page 15: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/15.jpg)
October 1, 2009
![Page 16: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/16.jpg)
![Page 17: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/17.jpg)
July 10,, 2008
![Page 18: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/18.jpg)
![Page 19: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/19.jpg)
![Page 20: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/20.jpg)
![Page 21: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/21.jpg)
![Page 22: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/22.jpg)
![Page 23: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/23.jpg)
![Page 24: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/24.jpg)
![Page 25: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/25.jpg)
![Page 26: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/26.jpg)
![Page 27: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/27.jpg)
![Page 28: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/28.jpg)
![Page 29: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/29.jpg)
![Page 30: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/30.jpg)
![Page 31: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/31.jpg)
![Page 32: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/32.jpg)
![Page 33: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/33.jpg)
January 1,, 2009
![Page 34: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/34.jpg)
![Page 35: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/35.jpg)
![Page 36: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/36.jpg)
![Page 37: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/37.jpg)
![Page 38: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/38.jpg)
![Page 39: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/39.jpg)
![Page 40: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/40.jpg)
![Page 41: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/41.jpg)
![Page 42: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/42.jpg)
![Page 43: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/43.jpg)
![Page 44: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/44.jpg)
Chest 2010;137;544-551
![Page 45: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/45.jpg)
seven RCT studies that included 11,425 patients.
![Page 46: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/46.jpg)
![Page 47: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/47.jpg)
![Page 48: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/48.jpg)
![Page 49: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/49.jpg)
![Page 50: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/50.jpg)
![Page 51: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/51.jpg)
![Page 52: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/52.jpg)
![Page 53: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/53.jpg)
![Page 54: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/54.jpg)
![Page 55: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/55.jpg)
JAMA, March 3, 2010—Vol 303, No. 9
![Page 56: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/56.jpg)
![Page 57: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/57.jpg)
![Page 58: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/58.jpg)
JAMA. 2010;303(8):739-746
![Page 59: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/59.jpg)
![Page 60: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/60.jpg)
![Page 61: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/61.jpg)
![Page 62: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/62.jpg)
![Page 63: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/63.jpg)
![Page 64: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/64.jpg)
![Page 65: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/65.jpg)
![Page 66: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/66.jpg)
JAMA. 2009;302(18):1977-1984
![Page 67: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/67.jpg)
![Page 68: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/68.jpg)
The COIITSS Study InvestigatorsJAMA. 2010;303(4):341-348
![Page 69: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/69.jpg)
![Page 70: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/70.jpg)
![Page 71: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/71.jpg)
![Page 72: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/72.jpg)
![Page 73: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/73.jpg)
Crit Care Med 2009 Vol. 37, No. 6
![Page 74: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/74.jpg)
Crit Care Med 2009 Vol. 37, No. 9
![Page 75: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/75.jpg)
![Page 76: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/76.jpg)
Crit Care Med 2010 Vol. 38, No. 4
![Page 77: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/77.jpg)
Avoid
![Page 78: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/78.jpg)
Crit Care Med 2009 Vol. 37, No. 6
![Page 79: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/79.jpg)
![Page 80: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/80.jpg)
Crit Care Med 2009 Vol. 37, No. 2
Total cohort number 66,184
![Page 81: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/81.jpg)
![Page 82: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/82.jpg)
Crit Care Med 2010 Vol. 38, No. 3
![Page 83: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/83.jpg)
![Page 84: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/84.jpg)
![Page 85: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/85.jpg)
Crit Care Med 2009 Vol. 37, No. 5
![Page 86: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/86.jpg)
![Page 87: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/87.jpg)
![Page 88: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/88.jpg)
![Page 89: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/89.jpg)
Crit Care Med 2010 Vol. 38, No. 2
![Page 90: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/90.jpg)
155/255 survival 61%
![Page 91: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/91.jpg)
Crit Care Med 2009 Vol. 37, No. 3
![Page 92: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/92.jpg)
![Page 93: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/93.jpg)
Crit Care Med 2009 Vol. 37, No. 9
![Page 94: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/94.jpg)
Overall, 22% (n 71,486) of patients developed acute kidney injury
(Stage I: 17.5%; Stage II: 2.4%; Stage III: 2%)
Odds of death associated with AKI in ICU
![Page 95: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/95.jpg)
Crit Care Med 2010 Vol. 38, No. 2
![Page 96: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/96.jpg)
The need for early serial IAP monitoring when IAH/ACS risk factors are present
Improving abdominal wall compliance through sedation, analgesia, and pharmacologic paralysis
Evacuating intraluminal contents through nasogastric or rectal decompression
Evacuating abdominal fluid collections via percutaneous drainage
Correcting positive fluid balance through the use of hypertonic fluids, colloids, and careful diuresis
Supporting organ function vasopressors and judicious goal-directed fluid resuscitation to maintain an abdominal perfusion pressure (calculated as mean arterial pressure IAP) 60 mm Hg
Early surgical intervention when IAP exceeds 25 mm Hg
![Page 97: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/97.jpg)
![Page 98: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/98.jpg)
Crit Care Med 2009 Vol. 37, No. 2
![Page 99: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/99.jpg)
Score Variables Points
Predisposition COPD or Immunosuppression
1
Age > 70 ys 1
Insult Bacteremia 1
Multilobar opacities on radiograph
1
Response Shock 1
Severe hypoxemia 1
Organ dysfunction Acute renal failure 1
Respiratory distress syndrome
1
Critical Care Medicine: February 2009 - Volume 37 - Issue 2 - pp 456-462
Range 0-8 points
![Page 100: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/100.jpg)
Critical Care Medicine: February 2009 - Volume 37 - Issue 2 - pp 456-462
HOMEHOSPITAL
ICU?CARE
![Page 101: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/101.jpg)
Crit Care Med 2009 Vol. 37, No. 8
![Page 102: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/102.jpg)
![Page 103: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/103.jpg)
![Page 104: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/104.jpg)
![Page 105: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/105.jpg)
![Page 106: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/106.jpg)
![Page 107: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/107.jpg)
Crit Care Med 2009 Vol. 37, No. 9
![Page 108: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/108.jpg)
![Page 109: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/109.jpg)
Crit Care Med 2009 Vol. 37, No. 5
![Page 110: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/110.jpg)
24%
![Page 111: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/111.jpg)
Crit Care Med 2009 Vol. 37, No. 1
![Page 112: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/112.jpg)
![Page 113: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/113.jpg)
Crit Care Med 2010 Vol. 38, No. 2
![Page 114: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/114.jpg)
![Page 115: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/115.jpg)
![Page 116: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/116.jpg)
Crit Care Med 2009 Vol. 37, No. 4
![Page 117: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/117.jpg)
![Page 118: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/118.jpg)
Crit Care Med 2009 Vol. 37, No. 5
![Page 119: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/119.jpg)
![Page 120: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/120.jpg)
Crit Care Med 2009 Vol. 37, No. 5
![Page 121: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/121.jpg)
Total parenteral nutrition X1 Surgery X1 Multifocal Candida colonization X1 Severe sepsis X 2.
![Page 122: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/122.jpg)
![Page 123: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/123.jpg)
![Page 124: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/124.jpg)
![Page 125: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/125.jpg)
![Page 126: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/126.jpg)
![Page 127: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/127.jpg)
![Page 128: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/128.jpg)
![Page 129: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/129.jpg)
![Page 130: Multicenter, randomized, double-blind low-dose vasopressinNorepinephrine 396 patients 382 patients 28 day mortality](https://reader038.vdocument.in/reader038/viewer/2022110322/56649d0c5503460f949e0233/html5/thumbnails/130.jpg)